Retatrutide

Wichtigste Eigenschaften

Wirkungsweise

Retatrutide is a first-in-class triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors simultaneously. The addition of glucagon receptor activation enhances energy expenditure and fat oxidation beyond what dual agonists achieve. Phase 2 trials showed unprecedented weight loss of up to 24% body weight.

Forschungsergebnisse

• •Phase 2 trial showed 24.2% weight loss at highest dose (48 weeks)
• •Triple agonist: GIP + GLP-1 + glucagon receptors
• •Greater weight loss than both semaglutide and tirzepatide in early data
• •Phase 3 trials ongoing (TRIUMPH program)
• •May benefit liver fat reduction (MASLD/NASH)

Rechtlicher Status

Retatrutide is an investigational drug in Phase 3 clinical trials by Eli Lilly. Not yet approved in any country. Research-grade available from peptide suppliers.

Preisvergleich: Retatrutide (4 Angebote)